Related Experiment Video

Updated: Jan 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non-Small Cell Lung Carcinogenesis

Tianshun Zhang1, Ruihua Bai1,2, Qiushi Wang1

  • 1The Hormel Institute, University of Minnesota, Austin, Minnesota.

Cancer Prevention Research (Philadelphia, Pa.)
|September 27, 2019
PubMed

Insights

Fluvastatin, a statin drug, shows promise in preventing and treating non-small cell lung cancer (NSCLC). It targets HMG-CoA reductase (HMGCR), inhibiting NSCLC tumor growth and inducing cancer cell death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer is a leading cause of cancer mortality globally.
  • Effective preventive agents for lung cancer are limited, necessitating research into novel therapeutic targets.
  • Non-small cell lung cancer (NSCLC) represents the majority of lung cancer cases.

Purpose of the Study:

  • To investigate the role of 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR) in NSCLC tumorigenesis.
  • To evaluate the potential of fluvastatin, an HMGCR inhibitor, as a chemopreventive or therapeutic agent for NSCLC.

Main Methods:

  • Assessed HMGCR expression in human lung adenocarcinoma tissues.
  • Utilized gene knockdown and fluvastatin treatment in NSCLC cell lines and animal models.
  • Analyzed the effects on cell growth, apoptosis, and key signaling pathways (Braf/MEK/ERK1/2, Akt).

Main Results:

  • HMGCR was found to be overexpressed in lung adenocarcinoma tissues.
  • HMGCR knockdown inhibited NSCLC cell growth and induced apoptosis in vitro and in vivo.
  • Fluvastatin suppressed NSCLC cell proliferation and induced apoptosis by inhibiting HMGCR-driven signaling pathways.
  • Fluvastatin demonstrated efficacy in reducing tumor growth in both carcinogen-induced and patient-derived xenograft lung cancer models.

Conclusions:

  • HMGCR is a critical driver of NSCLC tumorigenesis.
  • Fluvastatin effectively inhibits NSCLC progression through HMGCR targeting.
  • Fluvastatin holds significant potential as a chemopreventive or therapeutic drug for NSCLC, warranting clinical investigation.

More Related Videos

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

7.7K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.1K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.8K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.7K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
466